Identification of 7-(4′-Cyanophenyl) indoline-1-benzenesulfonamide
as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cells

Tung-Yun Wu1, Ting-Yu Cho2, Chung-Kuang Lu3, Jing-Ping Liou4 & Mei-Chuan Chen1,2

Targeting cellular mitosis in tumor cells is an attractive cancer treatment strategy. Here, we report that B220, a synthetic benzenesulfonamide compound, could represent a new mitotic inhibitor for the treatment of colorectal cancer. We examined the action mechanism of B220 in the colorectal carcinoma HCT116 cell line, and found that treatment of cells with B220 caused cells to accumulate in G2/M phase, with a concomitant induction of the mitotic phase markers, MPM2 and cyclin B1. After 48 h of B220 treatment, cells underwent apoptotic cell death via caspase-3 activation and poly(ADP ribose) polymerase (PARP) cleavage. In addition, B220 inhibits autophagy by blocking conversion of microtubule-associated protein 1 light chain 3 (LC3-I) to LC3-II and inhibiting autophagic flux. Notably, blockade of autophagy by pharmacological inhibition or using an Atg5-targeting shRNA reduced B220-induced cytotoxicity. Conversely, the autophagy inducer NVP-BEZ235 shows a synergistic interaction with B220 in HCT116 cells, indicating autophagy was required for the observed cell death. In summary, these results indicate B220 combined with the induction of autophagy using the dual PI3K/mTOR inhibitor, NVP-BEZ235, might be an attractive strategy for cancer therapy, and provides a framework for further development of B220 as a new therapeutic agent for colon cancer treatment.

Anti-mitotic agents have been used clinically to treat cancer for decades1,2. These chemotherapeutic drugs are designed to disrupt cancer cell microtubule dynamics and cause cell-cycle arrest, thereby inhibiting the hyperproliferative status of these cells and subsequently inducing cell death3. Although unwanted side effects of anti-mitotic drugs have been considered a key problem in the clinic, the impressive success of these agents against a variety of malignancies and the valuable scientific insights gained highlight their continuing importance in human diseases4–7. As with many antitumor drugs, the mechanism of action of anti-mitotic drugs involves the induction of cell cycle arrest at G2/M phase accompanied by Cdk1/cyclin B1 complex activation8. Induction of aberrant mitosis in tumor cells is frequently followed by significant apoptotic cell death9. Apoptosis is classified as Type I programmed cell death (PCD) and is mainly characterized with DNA fragmentation and chromatin condensation10. Autophagy, recognized as Type II PCD, is characterized by autophagosome formation and subsequent fusion with lysosomes, and serves to eliminate cellular proteins and cytoplasmic organelles11. It has been reported that autophagy is associated with different human pathologies, including cancer and neurodegenerative diseases12,13. Several studies have shown that autophagy is critical in the regulation of cancer progression and in determining the response of malignant cells to anticancer therapy14,15. The central regulator of autophagy is the

---

1Ph.D. Program for the Clinical Drug Discovery from Botanical Herbs, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. 2Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. 3National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan. 4School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Correspondence and requests for materials should be addressed to M.-C.C. (email: mcchen1250@tmu.edu.tw)
mammalian target of rapamycin (mTOR) pathway, which, when activated, negatively regulates autophagy to inhibit formation of autophagosomes. Conversely, autophagy-related gene (Atg)-6, also known as beclin-1, can initiate autophagy by associating with vacuolar sorting protein 34 (Vps34), a class III phosphoinositide 3-kinase (PI3K), to recruit other Atg products that are essential for autophagosome formation. During autophagy initiation, the Atg5-Atg12-Atg16 complex promotes the conversion of cytosolic protein light chain 3 (LC3-I) to the membrane-bound form, LC3-II, through lipidation. Thus, autophagy could potentially be suppressed by Atg5 inactivation or pharmacological inhibition of the class III PI3K inhibitor wortmannin. In contrast, inhibition of mTOR by rapamycin blocks the interaction of Atg13 with ULK1 (unc-51 like autophagy-activating kinase 1) to activate the autophagy pathway. Many anticancer agents, including temozolomide, camptothecin, ionizing radiation and anti-mitotic drugs, have been reported to induce the autophagy pathway in cells. It has been demonstrated that modulation of the autophagy pathway can potentiate the cytotoxicity of anticancer therapeutics against malignant cells.

Here, we identified B220 [7-[(4′-cyano phenyl)-indoline-1-benzensulfonamide] as a potent mitotic inhibitor that causes cell cycle arrest and significant cytotoxicity in HCT116 colorectal cancer cells. Our findings indicate that B220 inhibits autophagic activity and acts synergistically in combination with an autophagy inducer to enhance apoptotic cell death.

Results
B220 suppresses cell growth and colony formation in HCT116 colorectal cancer cells. To determine the in vitro antitumor activity of B220, we performed colony-formation assays using several cancer cell lines. As shown in Fig. 1A and B, B220 exerted an inhibitory effect on the colony-forming abilities of drug-treated cells, suggesting irreversible growth arrest and reproductive cell death. Notably, this cell-killing effect of B220 was more prominent in HCT116 colorectal cancer cells than in prostate cancer PC3 and non-small-cell lung cancer A549 cells (Fig. 1A and B), making HCT116 cells an appropriate model for assessing the effects of B220 and its underlying molecular mechanism of action. Subsequent SRB (sulforhodamine B) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays in HCT116 cells treated with different concentrations of the drug revealed that B220 suppressed the proliferation of HCT116 cells with submicromolar IC50 values (Fig. 1C and D). However, treatment with B220 at high concentration (10 μM) did not cause severe cytotoxicity toward normal colon FHC cells (Fig. 1E). Together, our findings show that B220 exerts significant cytotoxicity against HCT116 colorectal cancer cells and show selectivity for cancer cells.

B220 induces mitotic arrest followed by apoptosis in HCT116 colorectal cancer cells. To investigate the mechanism underlying B220-induced repression of cell growth, we examined the effects of B220 on cell cycle progression using flow cytometry. Cells began to accumulate in G2/M phase at 6 h after treatment; after 24 h, this peak shifted from G2/M to an apoptotic subG1 phase (Fig. 2A and B). Consistent with this, expression levels of the general mitotic markers, MPM-2 and cyclin B1, were induced in a concentration-dependent manner (Fig. 2C), peaking between 6 and 24 h after B220 treatment (Fig. 2D). Progression from G2 to M phase is initiated by activation of the Cdk1/cyclin B1 heterodimer complex, whose activity is regulated primarily by the kinase Weel and phosphatase Cdc25c, and is maintained from prophase to metaphase. Thus, in addition to significantly increasing MPM2 and cyclin B1 expression, B220 treatment similarly induced activating phosphorylation of Cdk1 residue Thr161, dephosphorylation of the inhibitory Cdk1 residue Tyr15, dephosphorylation of Cdc25c, and phospho-Cdk1 (T161), PLK1 and phospho-Aurora kinase, while decreasing the levels of phospho-Cdk1 (Y15) and phospho-Cdc25c (S216). Furthermore, the similar effects can be detected in different cancer cell lines (Supplementary Fig. 1), indicating B220 activates the Cdk1/cyclin B1 complex in cancer cells.

The Bcl-2 protein family includes anti- and pro-apoptotic members that control the balance of life-or-death cellular “decisions” by participating in the regulation of mitotic arrest in cells treated with an apoptotic stimulus. Here, we found that expression of the anti-apoptotic proteins, Bcl-2, Mcl-1 and Bcl-xl, decreased after 12 h of treatment with B220 (Fig. 3A and B). In contrast, levels of phospho-Bcl-2 (Ser70), which is known to induce apoptosis, were increased by drug treatment (Fig. 3A and B). Expression of Bad, another pro-apoptotic protein, was not appreciably altered by B220 in HCT116 cells (Fig. 3A and B). Notably, the subG1 phase showed a dramatic induction after 48 h of treatment (Fig. 2B) in parallel with significant activation of caspase-3, -8, and -9, and poly-(ADP-ribose) polymerase (PARP) (Fig. 3C and D). Taken together, these results indicate that B220 induces cell cycle arrest at the G2/M phase, inhibits anti-apoptotic proteins, and triggers apoptotic cell death.

B220 inhibits autophagosomal formation and decreases autophagic flux in cells. It is well known that autophagy plays important roles in cellular functions by degrading cytoplasmic components via the lysosome-dependent pathway. Several reports have shown that mitotic inhibitors can activate pro-cell death or pro-survival autophagy depending on cellular context. Here, we examined the ability of B220 to facilitate the conversion of LC3-I to LC3-II, an essential step in autophagosomal formation, and promote the expression of Atg5, which is responsible for autophagy initiation, in colorectal HCT116 cells. As shown in Fig. 4A, B220 decreased LC3-I protein expression levels without changing Atg5 levels, suggesting that B220 exerts an inhibitory effect on autophagy. To further elucidate the effects of drug treatment on autophagosomal formation and the association between autophagosomes and lysosomes, we analyzed the colocalization of autophagosomes and lysosomes in CWR22Rv1 cells stably expressing a fusion protein of green fluorescent protein (GFP) and LC3 (GFP-LC3) using deconvolution fluorescence microscopy. Rapamycin, which induces autophagosome formation, and bafilomycin A1, which blocks fusion of autophagosomes with lysosomes, were included as reference compounds. As shown in Fig. 4B, rapamycin-induced formation of GFP-LC3 puncta, as evidenced by the clear presence of green dots in
cells. Importantly, some colocalization of autophagosomes and lysosomes (yellow dots) was also observed, indicating that induction and degradation of autophagosomes occurred simultaneously in rapamycin-treated cells. In contrast, bafilomycin A1-treated cells exhibited accumulation of autophagosome puncta and significant induction of lysosome (LysoTracker staining), but colocalization of autophagosome and lysosome was barely detectable, reflecting block of autophagosome fusion with lysosomes. Interestingly, cells treated with B220 did not show an appreciable change in autophagosome (GFP-LC3 puncta) accumulation in cells compared with control cells, suggesting that B220 did not induce autophagy. Using a three-dimensional (3D) analysis to further clarify the interaction between autophagosomes and lysosomes, we found that B220 treatment interfered the fusion of autophagosomes and lysosomes, as evidenced by the lack of association between green and red dots (Fig. 4C).}

Figure 1. B220 suppresses colony formation and cell viability in colorectal cancer HCT116 cells. (A, B) Representative images showing B220-mediated inhibition of colony formation inhibits by three different tumor cells lines (A) and quantification of colony numbers (n = 3), expressed as a percentage of controls (B). (C) B220 significantly inhibited the growth of HCT116 cells. Cells were incubated with or without the indicated concentrations of B220 for 48 h, and cell growth was evaluated by SRB assay. (D) Effects of B220 on the viability of A549 cells. (E) Viability of normal colon FHC cells following treatment with B220. Cells were treated with DMSO (CTL) or different concentrations of B220 for 48 h, and cell viability was analyzed by MTT assay. Data are expressed as means ± S.D. of at least three independent experiments. *P < 0.05; **P < 0.01; and ***P < 0.001 compared with the control group.
together, these findings suggest that B220 is an autophagy inhibitor. To further investigate the role of autophagy in B220-induced cytotoxicity, we used a pharmacological approach, blocking autophagy with the class III PI3K inhibitor wortmannin and inducing autophagy with the mTOR inhibitor rapamycin. Wortmannin-induced inhibition of class III PI3K resulted in a decrease in LC3-I (Fig. 4D, lane 7), whereas rapamycin-induced autophagy mediated by inhibition of mTOR caused LC3-I and -II formation (Fig. 4E, lane 7). Cotreatment with B220 further potentiated the wortmannin-induced reduction in LC3-I expression (Fig. 4D, lane 8 and 9) and rapamycin-induced increase in LC3-I formation (Fig. 4E, lane 8 and 9), suggesting that B220 inhibits autophagosome formation under both autophagy-activated and -inactivated scenarios. Notably, the combination of B220
with the autophagy inhibitor wortmannin for 24 h attenuated the B220-induced accumulation of γH2AX, a cellular marker of DNA-double strand breaks (Fig. 4D). In contrast, the combination of B220 with the autophagy inducer rapamycin potentiated B220-induced formation of γH2AX (Fig. 4E). These findings suggest that targeting the modulation of autophagy plays an important role in B220-induced cell death in HCT116 cells, in which simultaneous induction and inhibition of autophagy may enhance B220-induced apoptosis.

Atg5 knockdown reduces B220-induced apoptosis in HCT116 cells. To further investigate the role of autophagy in B220-induced cell death, we inhibited autophagy initiation in HCT116 cells by knocking down Atg5. As shown in Fig. 5A, knockdown (KD) of Atg5 expression rescued B220-induced suppression of cell viability (left panel) and reversed B220-induced accumulation of γH2AX and activation of PARP and caspase 3 (right panel), suggesting that the Atg5 autophagy pathway enhances B220-induced cell death. Moreover, treatment with B220 for 24 h lead to a dramatic decrease in cell numbers in wild-type mouse embryo fibroblasts (MEFs), without causing an obvious change in cellular morphology or cell death in Atg5-knockout (KO) MEFs (Fig. 5B). Cell viability was similarly significantly increased in B220-treated Atg5-KO MEFs compared with wild-type MEFs following treatment for 48 h (Fig. 5C, left panel). Likewise, B220-induced apoptotic cell death was significantly reduced in Atg5-KO MEFs (Fig. 5C, right panel). Taken together, these findings indicate that inhibition of autophagy through deprivation of Atg5 greatly reduces B220-induced cell death.
Autophagy induction with the combined PI3K and mTOR inhibitor NVP-BEZ235 potentiates B220-induced cell death. Our findings suggest the possibility that combining B220 with an autophagy inducer would enhance B220-induced cell death effects. To test this, we cotreated cells with B220 and the dual PI3K/mTOR inhibitor, NVP-BEZ235. Both 2.5 and 5 µM NVP-BEZ235 induced significant autophagy in HCT116 cells after a 24-h treatment, as evidenced by LC3-II formation (Fig. 6A). An assessment of the effect of different dosing schedules of B220 and NVP-BEZ235 on the viability of HCT116 cells showed that, compared with B220 or NVP-BEZ235 alone, treatment with B220 plus NVP-BEZ235 with all three exposure-schedules decreased viability (Fig. 6B–D). In each case, combination index (CI) values were less than 1, indicating a synergistic interaction between B220 and NVP-BEZ235. Cotreatment with B220 and NVP-BEZ235 for 48 h resulted in CI values ranging from 0.5 to 0.9 (Fig. 6B, a–d). These CI values were improved to 0.1–0.3 by cotreatment with B220 and NVP-BEZ235 for 24 h followed by B220 alone for a total of 48 h (Fig. 6C, a–d). Notably, B220 for 24 h followed...
by addition of NVP-BEZ235 for a total of 48 h exerted the greatest synergy; under these conditions, all CI values were approximately 0.1 (Fig. 6D, a–d), indicating that exposure to B220 before NVP-BEZ235 produces the most effective synergistic interaction in HCT116 cells. Subsequent Western blot analyses revealed that this optimal combination therapy dosing with B220 and NVP-BEZ235 significantly potentiated apoptosis. As shown in Fig. 6E, NVP-BEZ235 alone induced autophagy without causing obvious activation of PARP or caspase-3, whereas combination treatment increased responsiveness to B220 in association with significant activation of PARP and caspase-3. Collectively, these findings show that B220 inhibits autophagy pathways in colorectal cells, and that combination therapy with the autophagy inducer NVP-BEZ235 enhances B220 cytotoxicity.

Discussion

Previous studies have shown that various anti-mitotic agents possess promising, wide-spectrum activity against different types of malignancies. Given the many challenges posed by the development of drug resistance...
during therapy, the US Food and Drug Administration (USFDA) has approved some novel anti-mitotic therapeutic agents for restoring efficacy lost due to drug resistance (e.g., ixabepilone and eribulin), and a number of ongoing studies seek to achieve better clinical values so as to solve existing problems. B220 has been shown to display effective antiproliferative activity against numerous cancer cell lines, including multidrug resistant (MDR)-positive cells, which overexpress P-glycoprotein 170 (p-gp170)/MDR. In addition, B220 causes tubulin depolymerization and shows strong binding affinity for the colchicine-binding domain. In this study, we clearly showed that B220 causes cell cycle arrest at G2/M phase and apoptotic cell death in HCT116 colorectal cancer cells. Parallel results obtained from flow cytometry analyses showed that B220 activates mitotic markers, including cyclin B1 and MPM2. Moreover, increased levels of Thr161-phosphorylated (activated) Cdk1 and decreased levels of Tyr15-phosphorylated (inhibited) Cdk1 indicate that accumulation of activated Cdk1 in cells peaks after 18 h of treatment with B220. Our data further showed a close correlation between an altered cell cycle distribution, analyzed by flow cytometry (Fig. 2B), and mitotic arrest, determined by Western blotting (Fig. 2D).

Figure 6. The autophagy inducer NVP-BEZ235 enhances B220-induced cytotoxicity in HCT116 cells. (A) NVP-BEZ235 (NVP) induced the conversion of endogenous LC3-I to LC3-II. (B–D) Synergistic effects of three different schedules of B220 and NVP-BEZ235 treatment on cytotoxicity in HCT116 cells. Cells were treated with the indicated compounds at the indicated concentrations for 48 h, and cytotoxicity was evaluated by MTT assay. (E) Apoptotic effects of B220 plus NVP-BEZ235. Cells were treated using the combination exposure schedule shown in (D), and protein lysates were analyzed by Western blotting using the indicated antibodies.
Our results further showed downregulation of pro-survival Bcl-2 and induction of Bcl-2 phosphorylation by B220. In addition to the well-known role of Bcl-2 family proteins in regulating permeabilization of the mitochondrial outer membrane\(^5\), the role of phosphorylation of Bcl-2 at Ser70 has been widely discussed. It has been demonstrated that CDK1 may be responsible for phosphorylation of Bcl-2 at Ser70, which augments the antiapoptotic effect of Bcl-2\(^3\). In addition, it has been demonstrated that the Bcl-2 Ser70 phosphorylation site is required to maintain the tight association between Bax and Bcl-2 necessary to prevent apoptosis\(^4\). However, it has also been shown that blocking Bcl-2 Ser70 phosphorylation by expressing a Bcl-2 Ser70 mutant failed to protect against histone deacetylase (HDAC) inhibition-induced cell death\(^2\). Further, several lines of evidence support the conclusion that Bcl-2 phosphorylation is simply a biomarker of anti-mitotic agents\(^3,4\), suggesting that the consequences of Bcl-2 phosphorylation might differ depending on cell type and stimulus.

It is well-known that microtubule-targeting agents induce apoptosis through JNK activation-dependent pathway. In our study, treatment with B220 for 24 h induces expression level of phospho-JNK (T183/Y185) in cells (Supplementary Fig. 2A). Combination with JNK inhibitor SP600125 reverses B220-induced expression of markers for G2/M cell cycle arrest (Supplementary Fig. 2A). In addition, cotreatment with JNK inhibitor for 48 h also attenuates B220-induced apoptotic cell death (Supplementary Fig. 2B). These results suggest activation of JNK contributes to B220-induced G2/M cell cycle arrest and apoptosis in HCT116 cells. However, B220 combined with JNK inhibitor did not change LC3 I expression level (Supplementary Fig. 2A), suggesting JNK activation did not play a major role in autophagy pathway.

Autophagy is an important catabolic pathway that is essential for maintaining cellular homeostasis\(^5\). The most common indicator of whether cells are undergoing activated autophagy signaling is the formation of double-membrane autophagic vesicles (autophagosomes), which can be detected by fluorescence microscopy in GFP-LC3–expressing cells\(^4\). However, an increase in the number of autophagosomes (i.e., green GFP puncta in GFP-LC3–expressing cells) may represent either autophagy activation or inhibition of a downstream step in autophagy that blocks fusion of autophagosomes and lysosomes\(^9\). Therefore, quantifying GFP-LC3 puncta is insufficient for evaluating autophagy activation. To carefully investigate B220-induced autophagic activity, we determined the “autophagic flux” by comparing the effects of the autophagy activator rapamycin and autophagy inhibitor bafilomycin A1, the latter of which blocks the fusion of autophagosomes and lysosomes, using deconvolution fluorescence microscopy (Fig. 4B). We clearly observed significant GFP puncta, indicating autophagosome formation, likely reflecting autophagy induction, in rapamycin- and bafilomycin A1-treated cells. However, LysoTracker staining in combination with an analysis of GFP puncta revealed that rapamycin increased autophagic flux by promoting fusion of autophagosomes and lysosomes (Fig. 4B, yellow), whereas bafilomycin A1 reduced autophagic flux, as evidenced by the presence of distinct autophagosomes and lysosomes in 3D images (Fig. 4C). Our findings showed that B220 decreases autophagic flux (Fig. 4C) and expression level of LC3-I protein (Fig. 4A and B), indicating that treatment with B220 inhibits autophagic activity in cells. In addition to formation of LC3-II and autophagosomes, degraded p62 is another biomarker for the detection of autophagy induction\(^5\). P62 is recruited with LC3-II to autophagosomes and is further degraded within the autolysosome to complete the autophagy pathway\(^5\). Further, it has been reported that microtubule destabilizers inhibit the fusion of autophagosomes and lysosomes, a microtubule-dependent step required to complete the autophagy process\(^3,6,9,50\). Given this, the expectation is that B220 would increase p62 accumulation in cells. Interestingly, however, B220 did not significantly alter p62 in HCT116 cells, but did induce a band shift after a 24-h treatment (Supplementary Fig. 3), suggesting that B220 causes a posttranslational modification of p62. Previous reports have shown that p62 is not only targeted for degradation by autophagy, but also participates in critical cellular functions through the regulation of physiologically important signaling factors that control diseases, such as cancer and insulin resistance\(^51\). It has been shown that phosphorylation of p62 at Thr269 and Ser272 by CDK1 maintains the activity of CDK1 necessary to regulate exit from mitosis\(^3,9\). Our findings revealed that B220-induced p62 phosphorylation can be blocked by cotreatment with the CDK1 inhibitor roscovitine, indicating B220 triggers CDK1-mediated p62 phosphorylation at Thr269 and Ser272 (Supplementary Fig. 3).

The role of autophagy in cancer has been widely discussed, and considerable evidence has shown that inhibition of autophagy may enhance the effects of anticancer agents\(^3,4,34,52\). We found that combining B220 with the autophagy inhibitor wortmannin decreased γH2AX formation (Fig. 4D). In contrast, the autophagy inducer rapamycin enhanced B220-induced γH2AX formation (Fig. 4E), suggesting that autophagy activation potentiates the anticancer activity of B220. To circumvent non-specific effects of pharmacological inhibitors, we next used Atg5–/– and Atg5–KO cells to investigate the role of autophagy in the anticancer activity of B220. These experiments showed that the ability of B220 to induce apoptotic cell death was greatly diminished in Atg5–/– and Atg5–KO MEFs (Fig. 5A–C). Moreover, knockdown of Atg5 greatly reduced B220-induced expression of markers for G2/M cell cycle arrest (Supplementary Fig. 4) and cytotoxicity (Fig. 5A). It is noteworthy that Atg5–KO MEFs provided better protection against B220-induced cell viability than Atg5–/– and Atg5–KO HCT116 cells did, suggesting that a basal level of Atg5-mediated autophagy may participate in B220-induced cell death.

NVP-BEZ235 has been reported as a dual PI3K/mTOR inhibitor that induces autophagy and exerts anticancer activity against several cancer cell types\(^5,6,7\). Previous studies have reported that different exposure schedules of drug combinations cause different results\(^4,9,58\), suggesting that schedule-dependent interactions between anticancer treatments should be studied carefully. Our current findings indicate that the combination of B220 and NVP-BEZ235 resulted in synergistic effects using three different exposure schedules (Fig. 6B–D). Notably, exposure to B220 before NVP-BEZ235 led to the most promising synergistic interaction in HCT116 cells (Fig. 6D and E), suggesting that the mechanism by which NVP-BEZ235 potentiates B220 cytotoxicity is related to the timing of autophagy initiation. It has been reported that appropriate modulation of autophagy by inhibiting cytoprotective autophagy or enhancing pro-death autophagy could potentiate the cytotoxicity of anticancer therapy in malignant cells\(^2,25\). Although previous studies have shown that the cytotoxicity of NVP-BEZ235 is enhanced by cotreatment with an autophagy inhibitor, owing to NVP-BEZ235-induced cytoprotective autophagy\(^5,37,40\),
NVP-BEZ235 has been demonstrated to induce pro-death autophagy in urothelial carcinoma cells\(^1\), suggesting that the outcome—pro-survival or pro-death autophagy—may be context dependent.

In summary, the current findings indicate that B220 is a highly effective anti-mitotic agent that reduces cell viability and autophagic activity in HCT116 cells. Autophagy induction by combined treatment with B220 and the autophagy inducer NVP-BEZ235 resulted in synergy between the two agents that significantly enhanced cytotoxicity and dramatically induced apoptotic cell death. Induction of autophagy in the context of a B220-induced reduction in autophagic activity may produce greater cellular stress, which in turn potentiates cell death. These results indicate that activation of autophagy might increase the efficacy of B220, suggesting a potential therapeutic strategy for enhancing the chemotherapeutic efficacy of this drug.

**Methods**

**Cell lines and reagents.** A549, PC3, HCT116, and normal intestinal epithelial fetal human colon (FHC) cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were maintained in 10% fetal bovine serum (FBS)-supplemented RPMI 1640 medium or DMEM/F12 medium (GIBCO, Grand Island, NY, USA) and 1% penicillin–streptomycin (GIBCO) at 37 °C in a humidified incubator containing 5% CO\(_2\). B220, 7-(4′-Cyano phenyl) indoline-1-benzenesulfonamide, was obtained from Professor Jing-Ping Liou (College of Pharmacy, Taipei Medical University, Taiwan). Antibodies against various proteins were obtained from the following sources: PARP (Poly-ADP-ribose polymerase), cyclin B1, Bcl-2, Bcl-xl, Mcl-1, PLK-1, Bad, and p62, were obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Bcl-2 (Ser70), caspase 8, caspase 9, caspase 10, and p62, were obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Beta-actin and MPM-2 were from Millipore (Billerica, MA, USA). Caspase 3 and was obtained from Cell signaling (Danvers, MA, USA). H2AX, phospho-cdc2 (Tyr15), phospho-cdc2 (Thr161), phospho-cdc25c (Ser216), Phospho-Aurora A (Thr288)/Aurora B (Thr232)/Aurora C (Thr198), and Atg5 were obtained from Cell signaling (Danvers, MA, USA). Bcl-2 (Ser70), caspase 8, caspase 9, caspase 10, and p62, were obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

**Cell viability assay.** Cells were seeded in 96-well plastic plates and exposed to indicated drugs for 48 h. Cell viability was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition was expressed as the percentage of surviving cells in drug-treated versus DMSO-treated control cells (which was considered as 100% viability). The IC\(_{50}\) value was the concentration resulting in 50% cell growth suppression by a 48-h exposure to drug(s) compared with untreated control cells. Interactions between B220 and NVP-BEZ235 were expressed as the combination index by the CompuSyn software: \(\text{CI} \leq 1\) represents synergistic cytotoxicity; \(\text{CI} > 1\) represents additive cytotoxicity; and \(\text{CI} > 1\) represents antagonistic cytotoxicity\(^62\).

**SRB (sulforhodamine B) assay.** Cells were seeded into 96-well plates and cultured overnight followed by the exposure to gradient concentrations of B220 for 48 h. Cells were then fixed \textit{in situ} with 10% trichloroacetic acid (TCA) to represent a measurement of the cell population at the time of drug addition (T0). After an additional 48 h incubation with or without B220 in medium with 5% FBS, the assay was terminated by 10% TCA. Unbound dye was removed by 1% acetic acid and the plates were air dried. Bound dye was subsequently solubilized with 10 mM trisma base, and the absorbance was read at a wavelength of 515 nm\(^63\).

**Clonogenic assay.** Cells were plated in 96 well (5000 cells per well) and exposed to DMSO or B220 at indicated concentrations for 24 h. The drugs were then washed away and cells were trypsinized and seeded in 6-well plates (500 cells/well) for continuing growing for 14 days. The colonies were fixed and stained with crystal violet (0.5% in 70% ethanol) and the experiments were repeated at least twice.

**FACScan Flow Cytometric analysis.** Cells were seeded in 6-well plates (2.5 × 10\(^4\)/well) and treated with DMSO or B220 at various concentrations for indicated times. Cells were washed with phosphate-buffered saline, fixed in ice-cold 70% ethanol at ~20 °C overnight, and stained with propidium iodide (80 ug/ml) containing Triton X-100 (0.1%, v/v) and RNase A (100 ug/ml) in phosphate-buffered saline. DNA content was analyzed with the FACScan and CellQuest software (Becton Dickinson, Mountain View, CA, USA).

**Immunoblotting and lentivirus expression system.** Cells were seeded in dishes and allowed to attach overnight. The cells were treated with drugs at indicated concentrations for indicated times. After the indicated exposure time, cells were lysed and the immunoblotting was performed as previously described\(^64\). Lentiviral shRNA expression plasmids of shAtg5 (TRCN0000151474, TRCN0000151963) were purchased from the National RNAi Core Facility (Academia Sinica, Taipei, Taiwan).

**Microscopic image acquisition.** For deconvolution microscopy, GFP-LC3-expressing CWR22-Rv1 cells (a generous gift from Mr. Chun A. Changou, Taipei Medical University) were seeded and treated with B220 (0.1 μM), Bafilomycin A1 (0.01 μM) or Rapamycin (0.01 μM) for 24 h in a 35 mm glass-bottomed dish (0.17 mm thick). LysoTracker (Thermo Fisher Scientific, Waltham, MA, USA) were used to stain Lysosome. For image capture, live cell was assessed by Wide-field Delta Vision deconvolution microscope (Applied Precision Inc., Eagle, ID, USA), equipped with inverted microscope (IX-71; Olympus, Tokyo, Japan), 100x/1.4 NA oil immersion objective lens, and camera (CoolSnap ES2; Photometrics, Tucson, AZ, USA). Images were reconstructed by using SoftWorx v6.1.1 software (Applied Precision Inc.), and analyzed with Velocity software (PrekinElmer, Waltham, MA, USA), as described previously\(^64\).
Statistics and data analysis. Each experiment was performed at least three times, and presentative data are shown. Data in bar graph are given as the means ± S.D. Means were checked for statistical difference using the t-test and P-values less than 0.05 were considered significant (*P < 0.05, **P < 0.01, ***P < 0.001).

Data Availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Jackson, J. R., Patrick, D. R., Dar, M. M. & Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? *Nat Rev Cancer*. 7, 107–117 (2007).
2. Wood, K. W., Cornwell, W. D. & Jackson, J. R. Past and future of the mitotic spindle as an oncology target. *Curr Opin Pharmacol*. 1, 370–377 (2001).
3. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. *Nat Rev Cancer*. 10, 194–204 (2010).
4. Morton, C. L. et al. Evaluation of ABT-751 against childhood cancer models in vivo. *Invest New Drugs*. 25, 285–295 (2007).
5. Swami, U., Shah, U. & Godl, S. Eribulin in Cancer Treatment. *Mar Drugs*. 13, 5016–5058 (2015).
6. Yang, C. H., Yap, E. H., Xiao, H., Fiser, A. & Horwitz, S. B. 2-(m-Azidobenzoyl)taxol binds differentially to distinct beta-tubulin isotypes. *Proc Natl Acad Sci USA* 113, 11294–11299 (2016).
7. Kovalevich, J. et al. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies. *J Pharmacol Exp Ther*. 357, 432–450 (2016).
8. Fourest-Lieuvin, A. et al. Microtubule regulation in mitotic: tubulin phosphorylation by the cyclin-dependent kinase Cdk1. *Mol Biol Cell*. 17, 1041–1050 (2006).
9. Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. *Cell Death Differ*. 15, 1153–1162 (2008).
10. Bursch, W., Ellinger, A., Gerner, C., Frohwein, U. & Schulte-Hermann, R. Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? *Ann N Y Acad Sci*. 926, 1–12 (2000).
11. Klionsky, D. J. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol*. 8, 931–937 (2007).
12. White, E. The role for autophagy in cancer. *J Clin Invest*. 125, 42–46 (2015).
13. Nixon, R. A. The role of autophagy in neurodegenerative disease. *Nat Med*. 19, 983–997 (2013).
14. Jiang, K. et al. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. *BMC Cancer*. 14, 551 (2014).
15. Thorburn, A., Thamm, D. H. & Gustafson, D. L. Autophagy and cancer therapy. *Mol Pharmacol*. 85, 830–838 (2014).
16. Pattingre, S., Expert, L., Biard-Piechaczyk, M. & Codogno, P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Biochimie*. 90, 313–323 (2008).
17. Yang, Z. J., Chee, C. E., Huang, S. & Sincrope, F. A. The role of autophagy in cancer: therapeutic implications. *Mol Cancer Ther*. 10, 1533–1541 (2011).
18. Matsushita, M. et al. Structure of Atg5:Atg16, a complex essential for autophagy. *J Biol Chem*. 282, 6763–6772 (2007).
19. Yang, Y. P. et al. Application and interpretation of current autophagy inhibitors and activators. *Acta Pharmacol Sin*. 34, 625–635 (2013).
20. Jung, C. H., Ro, S. H., Cao, J., Otto, N. M. & Kim, D. H. mTOR regulation of autophagy. *FEBS Lett*. 584, 1287–1295 (2010).
21. Kanazawa, T. et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. *Cell Death Differ*. 11, 448–457 (2004).
22. Paglin, S. et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res*. 61, 439–444 (2001).
23. Arthur, C. R. et al. Autophagic cell death, polyplody and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison. *Biochem Pharmacol*. 74, 981–991 (2007).
24. Abedin, M. J., Wang, D., McDonnell, M. A., Lehmann, U. & Kelekar, A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. *Cell Death Differ*. 14, 500–510 (2007).
25. Sui, X. et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. *Cell Death Dis*. 4, e838 (2013).
26. Apel, A., Herr, I., Schwarz, H., Rodemann, H. P. & Mayer, A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res*. 68, 1485–1494 (2008).
27. Castedo, M., Perfetti, J. L., Roumier, T. & Kroemer, G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. *Cell Death Differ*. 9, 1287–1293 (2002).
28. Golstein, R. M. et al. Cell cycle analysis and chromosomal localization of human Pkl1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. *J Cell Sci*. 107(Pt 6), 1509–1517 (1994).
29. Goldenson, B. & Crispino, J. D. The aurora kinases in cell cycle and leukemia. *Oncogene*. 34, 537–545 (2015).
30. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer*. 2, 647–656 (2002).
31. Zhou, L., Cai, X., Han, X., Xu, N. & Chang, D. C. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents. *Cell Biol Int*. 38, 737–746 (2014).
32. Maituri, M. C., Zalckvar, E., Kimchi, A. & Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. *Nat Rev Mol Cell Biol*. 8, 741–752 (2007).
33. Domenech, E. et al. AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. *Nat Cell Biol*. 17, 1304–1316 (2015).
34. Xi, G. et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. *Cancer Lett*. 307, 141–148 (2011).
35. Hadfield, J. A., Ducci, S., Hirst, N. & McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. *Prog Cell Cycle Res*. 5, 309–325 (2003).
36. Dybdal-Hargreaves, N. F., Risinger, A. L. & Mosberry, S. L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. *Clin Cancer Res*. 21, 2445–2452 (2015).
37. Ferrandina, G. et al. Novel drugs targeting microtubules: the role of epothilones. *Curr Pharm Des*. 18, 2793–2803 (2012).
38. Kanakkanthara, A., Northcote, P. T. & Miller, J. H. Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease. *Nat Prod Rep*. 33, 549–561 (2016).
39. Chang, J.-Y. et al. Synthesis and biological evaluation of 7-arylidinoline-1-benzensulfonamides as a novel class of potent anticancer agents. *MedChemComm*. 3, 152–155 (2010).
40. Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 family proteins. *Cold Spring Harb Perspect Biol*. 5, a008714 (2013).
41. Deng, X., Kornblau, S. M., Ruvolo, P. P. & May, W. S., Jr. Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. *J Natl Cancer Inst Monogr*. 30–37 (2001).
42. Dasmahapatra, G., Almenara, J. A. & Grant, S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. *Mol Pharmacol*. **69**, 288–298 (2006).

43. Ling, Y. H., Tornos, C. & Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. *J Biol Chem*. **273**, 18984–18991 (1998).

44. Haldar, S., Basu, A. & Croce, C. M. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. *Cancer Res.* **58**, 1609–1615 (1998).

45. Kondo, Y., Kanzawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer*. **5**, 726–734 (2005).

46. Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy research. *Cell*. **140**, 313–326 (2010).

47. Bjorkoy, G. et al. Monitoring autophagic degradation of p62/SQSTM1. *Methods Enzymol.* **452**, 181–197 (2009).

48. Tan, Q. et al. Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors. *Neoplasia*. **18**, 347–355 (2016).

49. Kimura, S., Noda, T. & Yoshimori, T. Dynamin-dependent movement of autophagosomes mediates efficient encounters with lysosomes. *Cell Struct Funct.* **33**, 109–122 (2008).

50. Jahreiss, L., Menzies, F. M. & Rubinsztein, D. C. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. *Traffic*. **9**, 574–587 (2008).

51. Rodriguez, A. et al. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. *Cell Metab*. **3**, 211–222 (2006).

52. Moscat, J. & Diaz-Meco, M. T. p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell*. **137**, 1001–1004 (2009).

53. Linares, J. F., Amanchy, R., Greis, K., Diaz-Meco, M. T. & Moscat, J. Phosphorylation of p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell proliferation. *Mol Cell Biol*. **31**, 105–117 (2011).

54. Lin, J. et al. Inhibition of autophagy enhances the anticancer activity of silver nanoparticles. *Autophagy*. **10**, 2006–2020 (2014).

55. Zhu, S. et al. Inhibiting autophagy potentiates the anticancer activity of IFNα1/IFNα2 in chronic myeloid leukemia cells. *Autophagy*. **9**, 317–327 (2013).

56. Seitz, C., Hugle, M., Cristofano, S., Tchoghandjian, A. & Fulda, S. The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. *Int J Cancer*. **132**, 2682–2693 (2013).

57. Chang, Z. et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. *Int J Mol Med*. **31**, 1449–1456 (2013).

58. Chen, S. H., Forrester, W. & Lahav, G. Schedule-dependent interaction between anticancer treatments. *Science*. **351**, 1204–1208 (2016).

59. Li, T., Ling, Y. H., Goldman, I. D. & Perez-Soler, R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. *Cin Clin Cancer Res*. **13**, 3413–3422 (2007).

60. Cerniglia, G. J. et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. *Mol Pharmacol*. **82**, 1230–1240 (2012).

61. Li, J. R. et al. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. *Toxicol Lett*. **220**, 267–276 (2013).

62. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res*. **70**, 440–446 (2010).

63. Chen, C. H. et al. Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. *Cancer Lett*. **315**, 1–11 (2012).

64. Changou, C. A. et al. Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. *Proc Natl Acad Sci USA*. **111**, 14147–14152 (2014).

Acknowledgements

We thank Core Facility Center of Taipei Medical University for the supports of deconvolution microscope. This research was supported by the Ministry of Science and Technology of the Republic of China (grant no. MOST-103-2320-B-038-030-MY3), and TMU102-AE1-B43 by Taipei Medical University.

Author Contributions

T.-Y.W. and M.-C.C. provide conception and designed the study. T.-Y.W. and T.-Y.C. performed the experiments and collected data. T.-Y.W., T.-Y.C., C.-K.L., and M.-C.C. analyzed and interpreted the data. J.-P.L. and C.-K.L. contributed chemical compounds and reagents. T.-Y.W., T.-Y.C., C.-K.L., J.-P.L., and M.-C.C. wrote and revised the manuscript critically for important intellectual content. All authors approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12795-5.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017